Support guide for symptom assessment in patients with myeloproliferative syndromes using the mpn-10 scale
Keywords:
Myeloproliferative neoplasms, Symptoms, MPN-10Abstract
Myeloproliferative neoplasms (PH-) – Myelofibrosis, Polycythemia Vera and Essential Thrombocythemia – represents a heterogeneous disorders of the hematopoietic system associated with debilitating symptoms with consequent reduction of the quality of life and negative impact on the daily activities of of patients. The National Comprehensive Cancer Network (NCCN) guidelines, based on the Myeloproliferative Neoplasm Symptom Assessment Form, Total Symptom Score (MPN-SAF TSS) tool, were initiated by some Portuguese hospitals and began monitoring and, systematically, evaluating the symptoms of these patients. This tool, validated for the Portuguese language, has been applied with the support of the nursing teams. In Nurses Focus Group model they discuss the main challenges in using the MPN-10 assessment tool, following which the present guide was developed. The most relevant aspects of the application of this tool were identified: 1) to take into account that it is a self-completion scale; 2) the tool aims to assess the impact of the symptom using numerical categories and 3) the healthcare professionals should not refer / induce the patient for comparison with previous evaluations. To facilitate the understanding of the MPN-10 and methodology of filling by the patient, additional information was developed on each of the symptoms for use by the health professional at the moment of information/clarification to the patient.
Downloads
References
Almeida A, Macedo A, Afonso C, Trindade MC, Pinho Vaz C, Montalvão A, Polo B, Araújo LF, Costa C, Guerra L. (Nov 2016). Tradução e validação linguística da ferramenta PMN10 para graduação de sintomas em doentes com Neoplasias Mieloproliferativas em Portugal. Poster presented at the SPH National Meeting. Aveiro, Portugal.
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611. PubMed PMID: 27956542.
Harrison, C.N et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematolo 2017 96.1653-1995
Arber DA et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405
Emanuel RM, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. J Clin Oncol. 2012; 30 (33): 4098-4103.
FDA. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Dec 2009; EMA. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man, 2014; EMA/CHMP/292464/2014
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Andreia Rocha, Cláudia Ricou , Elisabete Pereira, Elisabete Valério , Júan Sanchez, M. Jorge Freitas, Márcia Caeiro, Maria Sarmento , Marta Duarte, Sandra Ponte , Sónia Frias
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.